China NMPA Approves Bayer's Asundexin Tablets to Reduce Stroke Risk in Adults After Ischemic Stroke or High-Risk TIA

China's National Medical Products Administration has approved, through priority review, Asundexin Tablets, a Class 1 innovative drug from Bayer AG, marketed under the brand name Shuhuabo. The drug reduces stroke risk in adults with ischemic stroke or high-risk transient ischemic attack (TIA), excluding patients with cardioembolic stroke.